The global COVID-19 pandemic is currently underway. In December 2020, the European
Agency of Medicine (EMA) licensed the first Sars-CoV-2 vaccine. Therapeutic management …

Abstract Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is a matter of concern worldwide and a huge …

For some patients with SARS-CoV-2, the worst clinical damage is not caused by the virus
itself, but by an overactive inflammatory state. In fact, in some people the immune system …

Actuality The course of the novel coronavirus disease (COVID-19) is unpredictable. In some
cases, it manifests as increasing inflammation that leads to a cytokine storm and irreversible …

The search for effective COVID-19 management strategies continues to evolve. Current
understanding of SARS-CoV-2 mechanisms suggests a central role for exaggerated …

Colchicine has shown clinical benefits in the management of COVID‐19 via its anti‐
inflammatory effect. However, the exact role of colchicine in COVID‐19 patients is unknown …

Abstract Purpose of Review Coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, is a pandemic causing havoc …

Background Colchicine is an available, safe, and effective anti-inflammatory drug and has
been suggested as a COVID-19 treatment, but its usefulness in hospitalized severe COVID …

Currently, there is no widely acceptable and proven effective treatment for coronavirus
disease 2019 (COVID‐19). Colchicine has been shown to offer a benefit in reducing the …

Introduction Neutrophilia and high levels of proinflammatory cytokines and other mediators
of inflammation are common finds in patients with severe acute respiratory syndrome due to …